Identification of Post-Transcriptional Modulators of Breast Cancer Transcription Factor Activity Using MINDy

Thomas M. Campbell1‡, Mauro A. A. Castro2‡, Bruce A. J. Ponder1, Kerstin B. Meyer1*

1 Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, United Kingdom, 2 Bioinformatics and Systems Biology Lab, Federal University of Paraná (UFPR), Politecnic Center, Rua Alcides Vieira Arcovende, Curitiba, PR, Brazil

‡ Joint first authorship.
* Kerstin.Meyer@cruk.cam.ac.uk

Abstract

We have recently identified transcription factors (TFs) that are key drivers of breast cancer risk. To better understand the pathways or sub-networks in which these TFs mediate their function we sought to identify upstream modulators of their activity. We applied the MINDy (Modulator Inference by Network Dynamics) algorithm to four TFs (ESR1, FOXA1, GATA3 and SPDEF) that are key drivers of estrogen receptor-positive (ER+) breast cancer risk, as well as cancer progression. Our computational analysis identified over 500 potential modulators. We assayed 189 of these and identified 55 genes with functional characteristics that were consistent with a role as TF modulators. In the future, the identified modulators may be tested as potential therapeutic targets, able to alter the activity of TFs that are critical in the development of breast cancer.

Introduction

Modulator Inference by Network Dynamics (MINDy) is a gene expression profile-based method to identify genes that modulate the transcriptional programme of a given transcription factor (TF). That is, MINDy is able to systematically identify genes that encode proteins that affect a TF’s activity without affecting its mRNA abundance. Modulators may act on the translation efficiency of the mRNA into protein, post-translationally modify the TF, affect the cellular localisation or turnover of the TF, form a transcriptional complex with the TF thereby changing its activity, or compete for its DNA binding site. The MINDy algorithm was introduced by the lab of Andrea Califano [1] and has been used to identify post-transcriptional modulators of TF activity in human B-cells [2]. Briefly, the MINDy algorithm interrogates a large gene expression profile dataset in order to identify candidate modulator genes able to alter the relationship between a TF and its regulon (set of target genes). For each TF of interest, a candidate modulator is tested by MINDy. Gene expression profiles from each of a set of samples (here, individual tumours) are ranked by the expression of the selected modulator, M (Fig 1). Sets of samples with high and low expression of the modulator are then selected.
In each of the two sample sets, samples are then sorted according to TF expression and the extent of correlation in gene expression between the TF and its target genes is assessed. If the pattern of correlation differs significantly between M-high and M-low, then M is a modulator of the activity of that TF. The analysis also tests whether the modulator is a positive or negative one [1].

Here, we use the MINDy algorithm to identify modulators of the TFs ESR1, FOXA1, GATA3 and SPDEF (Fig 1). Each of these is an important driver of estrogen receptor-positive (ER⁺) breast cancer. In addition, these TFs are the master regulators (MRs) of the FGFR2 response, which is strongly associated with risk of breast cancer development [3,4]. ESR1, GATA3 and FOXA1 form part of the well-characterised estrogen receptor transcriptional network in ER⁺ breast cancer cells [5,6]. SPDEF is a novel co-regulator of the ESR1 transcriptional network. SPDEF is normally expressed in a range of epithelial cell types, especially in hormone-regulated tissues [7], and has been associated with cancer: SPDEF is overexpressed in breast cancer cells [8–10] but is often lost in high-grade, invasive tumours [11]. It was originally identified as a co-factor of the androgen receptor [12].

Having identified potential modulators of these TFs in ER⁺ breast cancer, we validate the MINDy findings with functional assays in order to demonstrate the biological relevance of our computational predictions.

Materials and Methods

MINDy algorithm

Modulators of transcription factor (TF) activity are assessed by conditional mutual information analysis as described elsewhere [1,2]. Briefly, this method takes a list of potential modulators and computes the conditional mutual information over the TF-target interactions of a given regulon. For each TF, the method measures the change in the mutual information between the TF and its targets conditioned to the gene expression of the modulator. The list of candidate modulators includes all genes annotated in the gene expression data, applying a modulator independence constraint to each test in order to exclude those candidates that are themselves correlated with the expression of the TF. The modulator inference was performed in R using the tri.condition function in the RTN package (http://bioconductor.org/packages/RTN/) with 1000 permutations. The analysis pipeline has three main steps: (1) compute a regulatory network to derive regulons; (2) re-compute all regulons conditioned on the knowledge of a given candidate modulator. This is the MINDy algorithm, which tests whether the TF-target mutual information changes conditioned on the presence/absence of the modulator (it computes the differential mutual information). Here we also use a bootstrap analysis to check the stability of the inferred modulated targets, that is, we check the frequency that the inferred modulated targets can be observed in different subsamples; and (3) test whether the number of modulated targets is greater than would be expected by chance using FET (Fisher’s Exact Test) statistics. This step also tests the association between the observed modulated targets and the TF-target strength using KS (Kolmogorov-Smirnov) statistics, which aims to check whether the modulation happens in the strongest TF-target interactions. As a cut-off we chose an adjusted P-value of <0.001. To generate Fig 1, MI was calculated to generate grey dots. The shift from the original is calculated as dMI, which is scaled so that values are comparable across all targets:

$$dMI = \frac{(MI_{\text{top}} - MI_{\text{bottom}})}{(MI_{\text{top}} + MI_{\text{bottom}})}$$
Fig 1. The MINDy algorithm. (A) Graphic representation of the MINDy analysis. For each tumour, gene expression activity is calculated for a given transcription factor (TF), a TF target (t) and a possible modulator (M), and represented as a vertical, coloured bar. Tumours are ranked by the expression value of the modulator. For the top 1/3 and bottom 1/3 of all tumours, samples are re-ranked by TF expression and mutual information (MI) between the TF and target is calculated. If similar MIs are obtained between the two groups no modulator activity is detected. However, if the MI value between the two groups is different, M has modulator activity.

Example of modulation:

| TF  | M   | t   | MI |
|-----|-----|-----|----|
|     |     | high| low|
|     |     | high| low|

(B and C) Schematics and overall results for two predicted FOXA1 modulators, ALDH3B and ARHGEF2. The plots show the distribution of MI for the entire set of FOXA1 targets. The grey circles show the scaled MI values obtained when assessing MI for a TF-target interaction across all tumours. Targets are ranked, showing those with the highest modulation effect.
The green circles represent the shift (MI_{shift}) in the MI and values are calculated as:

\[ MI_{shift} = MI_{original} + (MI_{original} \times dMI) \]

**Cell culture**

MCF-7 human breast cancer cells were cultured in DMEM (Invitrogen) supplemented with 10% FBS and antibiotics. T47D and ZR751 human breast cancer cells were cultured in RPMI (Invitrogen) supplemented with 10% FBS and antibiotics. HB2 mammary luminal epithelial cells were cultured in DMEM (Invitrogen) supplemented with 10% FBS, 5 \( \mu \)g/ml insulin, 1 \( \mu \)g/ml hydrocortisone and antibiotics. All cells were maintained at 37˚C, 5% CO\(_2\). All cell lines were from the CRUK Cambridge Institute collection and cell line identity was confirmed by STR genotyping.

**Quantitative RT-PCR**

1 \( \mu \)g of total RNA was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and qRT-PCR performed using cDNA obtained from 10 ng of total RNA. qRT-PCR was performed using an ABI 9800HT Sequence Detection System (Applied Biosystems) with SDS software version 2.3. All primers were specific for each gene of interest (Table 1). Amplification and detection were carried out in 384-well Optical Reaction Plates (Applied Biosystems) with Power SYBR Green Fast 2x qRT-PCR Mastermix (Applied Biosystems). All expression data were normalised to DGUOK expression. Primer-specificity was confirmed at the end of each qRT-PCR run through the generation of single peaks in melt-curve analysis. Data analysis was performed using the \( 2^{-\Delta\Delta CT} \) method [13].

**Western immunoblotting**

Cells were grown in 10 cm Petri dishes, washed in PBS and lysed on ice in RIPA buffer with cOmplete Mini EDTA-free protease inhibitor cocktail (Roche). Resulting cell lysates were passed through a fine-gauge syringe needle several times, centrifuged at 10,000 g for 1 minute and left at -80˚C at least overnight. Protein samples were separated by SDS-PAGE using 4–12% Bis-Tris gels (Novex) for 2.5 hours (30 minutes at 60 V, 120 minutes at 120 V) and transferred by electrophoresis using iBlot (Novex) for 7 minutes onto a nitrocellulose membrane (iBlot Gel Transfer Stacks; Novex). Successful transfer of protein was confirmed using

| Table 1. Primers used in qRT-PCR to determine mRNA expression. |
|---------------------|---------------------|---------------------|
| **Gene**           | **Forward primer (5'-3')** | **Reverse primer (5'-3')** |
| DGUOK              | GCTGGTGTTGGATGCTAATG | GGCTGAACTTCATGGTTATGG |
| SPDEF              | GTGCCTACATACCCGAGATC | GGTCCTCTGCCACAGAAGCC |
| FOXA1              | GGCGCTTGGCTGGCATAGC | GCACCGGGGAAGGGTTGTCG |
| FGFR2              | CTCAGTGAGAAGGATCAACAAGG | GTAGCCTCAAATGCAGAAGC |
| CCND1              | AGAACGCCGTCATCTACACCGACA | TGATCTGGTTTGTCCCTCCTGCC |

doi:10.1371/journal.pone.0168770.t001
Membranes were “blocked” at room temperature for 1 hour with 5% (w/v) dried milk in Tris-buffered saline (TBS) with 0.1% Tween-20 (TTBS), washed 3x with TTBS and probed with the relevant primary antibody (anti-SPDEF, 1:200, Santa Cruz sc-67022; anti-FOXA1, 1:1000, Abcam ab5089; anti-FGFR2, 1:200, Santa Cruz sc-122; anti-β- actin, 1:5000, Cell Signalung) in blocking solution at 4°C overnight. Membranes were then re-washed with TTBS 3x and incubated with appropriate HRP-conjugated secondary antibody (anti-rabbit, 1:10,000, Amersham; anti-goat, 1:2000, Dako) in blocking solution at room temperature for 90 minutes. Following further washing with TTBS, blots were treated with SuperSignal West Chemiluminescent Substrate (Thermo Scientific) and immunoreactive proteins detected by exposure to film (FUJIFILM).

**Transient transfection of siRNA**

Cells were transfected with ON-TARGETplus SMARTpool siRNA (Dharmacon) directed against SPDEF (L-020199-00), FOXA1 (L-010319-00), FGFR2 (L-003132-00), CCND1 (L-003210-00), MSL3 (L-012319-02), ARHGEF2 (L-009883-00) and a control non-targeting pool (D-001810-01) using Lipofectamine RNAiMax Reagent (Invitrogen), according to manufacturer’s protocol. Following addition of the transfection complexes, cells were incubated at 37°C, 5% CO₂ for 24–48 hours before experiments were performed.

**Transient transfection of siRNA for proliferation assays**

Proliferation assays were performed in 96-well reverse transfection (RTF) plates (Dharmacon) and rehydration of siRNA was performed according to manufacturer’s protocol. Briefly, lyophilised siRNA for each of the 189 modulators of SPDEF and FOXA1, identified by MINDy, was rehydrated in the RTF plates using cell culture medium and Lipofectamine RNAiMax Reagent (Invitrogen), and siRNA transfection complexes were allowed to form. 4000 cells per well were then added to the plates, ready for proliferation analysis. The complete list of modulators against which siRNAs were targeted is available in S1 Table.

**Proliferation assay**

Cells were plated at 4000 cells per well into 96-well plates and cell numbers monitored in real time by *in vitro* micro-imaging using an IncuCyte incubator (Essen BioScience), allowing for monitoring of cell proliferation by observing cell confluence. Images were taken every three hours and data consisted of an average of four separate images taken for each well. Assays were performed in triplicate on three separate occasions. Statistical analysis of proliferation data was performed using the `compareGrowthCurves` command in the `statmod` package in R (http://CRAN.R-project.org/package=statmod). Multiple testing correction was achieved using the Benjamini-Hochberg method.

**Molecular cloning**

Three repeats of the SPDEF DNA binding consensus sequence was cloned into a pLUC2CP Luciferase Reporter Vector (kindly donated by the lab of David Neal, CRUK Cambridge Institute), following Ascl/NheI digestion (Ascl-(ACA GTG TGC CCG GAT TAT CGA)₃-NheI), to generate a reporter construct in which luciferase gene expression is influenced by SPDEF protein binding. The orientation and sequence of the cloned plasmid was confirmed by DNA sequencing (GATC Biotech).
Luciferase reporter assay

MCF-7 cells were plated at 0.5x10^5 cells/well in 24-well dishes and left in complete medium until 50–70% confluent. If required, cells were first transfected with siRNA using Lipofectamine RNAiMax Reagent (Invitrogen), according to manufacturer’s protocol and left for 24 hours. Cells were then transfected with luciferase and β-galactosidase constructs together at a concentration of 0.5 and 0.1 μg per well, respectively, using FuGENE HD Transfection Reagent (Promega), according to manufacturer’s protocol. After 24 hours at 37°C, 5% CO₂, cells were lysed with Reporter Lysis Buffer (Promega) and luciferase and β-galactosidase assays were performed on a PHERAstar FS Microplate Reader (BMG LABTECH) using the appropriate assay kits (Promega), according to manufacturer’s protocol. Transfection of each reporter construct was performed in triplicate in each assay and a total of three assays were performed on three separate days.

Code availability

The source code developed in this study is publicly available from Bioconductor in the R package RTN (http://bioconductor.org/packages/RTN/).

Results

The MINDy algorithm identifies potential modulators of breast cancer risk TF activity

Previously, we have investigated TF involvement in modulating polygenic risk in breast cancer. We have identified 36 TFs whose regulons are significantly enriched for genes associated with breast cancer risk loci (termed “risk TFs”) [14], and four of these risk TFs (ESR1, FOXA1, GATA3 and SPDEF) have been identified as MRs of FGFR2-mediated risk in breast cancer [4]. In this study we applied the MINDy algorithm to ESR1, FOXA1, GATA3 and SPDEF, and their regulons. The MINDy algorithm (see materials and methods for details) was able to identify a total of 506 potential post-transcriptional modulators of ESR1, GATA3, FOXA1 and/or SPDEF activity. Of these 506 identified genes, 212 positively modulated one or several of the four TFs (Fig 2), 232 negatively modulated them (S1 Fig), and 62 lay in-between two or more of the TFs (we refer to these as the “in-modulators”), i.e. they were downstream of one of the TFs and upstream of another (S2 Fig). The vast majority of the positive and negative modulators that were identified affect the activity of FOXA1, with relatively few impacting on the activity of the other three TFs. We therefore chose to focus on FOXA1 for experimental validation of our results, and also SPDEF because it is a less well-studied, newly-identified ER⁺ breast cancer risk TF.

Experimental validation and set-up

Previous studies [14] demonstrated that both FOXA1 and SPDEF are required for proliferation of ZR751 ER⁺ breast cancer cells. To determine the relevance of the identified modulators we therefore examined if downregulation of the positive modulators would affect cell proliferation in a FOXA1 or SPDEF-dependent manner. We focused our analysis on positive modulators since, in already rapidly proliferating cell lines, inhibition of growth might be more easily detectable than a potential increase in proliferation. Moreover, given the dependence of ER⁺ cell lines on FOXA1, positive modulators would be more attractive therapeutic targets.

We first characterised SPDEF and FOXA1 expression and activity in three ER⁺ breast cancer cell lines (MCF-7, T47D and ZR751). Both SPDEF and FOXA1 mRNA and protein were expressed in all three ER⁺ breast cancer cell lines, and their expression levels were significantly
reduced following transfection of siRNA against the TFs (Fig 3A–3C). In all three ER\(^+\) cell lines, transfection of siRNA against SPDEF or FOXA1 also significantly reduced cell proliferation compared with transfection of a control, non-targeting siRNA sequence (Fig 3D–3F). This suggests that proliferation of the ER\(^+\) breast cancer cell lines was dependent on SPDEF and FOXA1 activity. In contrast, the HB2 cell line is a human mammary epithelial cell line with hardly detectable levels of SPDEF and very low levels of FOXA1 compared with ER\(^+\) breast cancer cell lines (Fig 4A–4C), whose growth does not depend on SPDEF and FOXA1 activity (Fig 4D). We therefore used HB2 cells as controls to establish whether the activity of the identified modulator was FOXA1 or SPDEF-dependent or occurred via a non-specific mechanism. In order to satisfy ourselves that siRNA is able to get into the HB2 cells, transfection experiments were performed. siRNA transfection in HB2 cells was efficient, as demonstrated by transfection of siGLO RED Transfection Indicator (Fig 4E). Also, transfection of siRNAs directed against \(\text{FGFR2}\) and \(\text{CCND1}\) significantly reduced levels of mRNA for these genes (Fig 4F) and reduced levels of FGFR2 protein (Fig 4G). Furthermore, HB2 cell proliferation was inhibited following transfection of siRNA directed against \(\text{CCND1}\), unlike with siRNA directed against \(\text{SPDEF}\) and \(\text{FOXA1}\) (Fig 4H).

The following criteria were used to select a list of modulators to validate. Firstly, only positive modulators were chosen (Fig 2). Secondly, all positive modulators of SPDEF that were...
Fig 3. SPDEF and FOXA1 expression and activity in ER+ breast cancer cell lines. (A and B) Relative mRNA expression of SPDEF (A) and FOXA1 (B) in MCF-7, T47D and ZR751 ER+ breast cancer cells following transfection with siRNA directed against SPDEF and FOXA1, respectively. All data were normalised to DGUOK expression (n = 10, two separate experiments, \( P < 0.001 \) (**)), one-way ANOVA and SNK correction, error bars = SEM). (C) Representative Western immunoblots showing expression of SPDEF, FOXA1 and \( \beta \)-actin proteins in MCF-7, T47D and ZR751 ER+ human breast cancer cell lines (n = 3 for all blots). (D-F) Growth curves for MCF-7 (D), T47D (E) and ZR751 cells (F) following transfection with siRNA directed against SPDEF and FOXA1. Cells were transfected with scrambled, non-targeting siRNA as a control (siCTL).
MINDy Analysis in Breast Cancer

A

B

C

D

E

F

G

H

Normalised SPDEF mRNA expression

Normalised FOXA1 mRNA expression

% Confluence

Normalised mRNA expression

% Confluence

MCF-7 T47D HB2

MCF-7 T47D HB2

MCF-7 HB2

MCF-7 HB2

50 37

50 37

50 37

50 37

SPDEF

FOXA1

β-actin

HB2 wCTL

HB2 wFGFR2

HB2 wFOX1

Time (h)

Time (h)

FGFR2

β-actin

siScrambled siRNA

siFGFR2 siCCND1

siFGFR2 siCCND1

PLOS ONE | DOI:10.1371/journal.pone.0168770 December 20, 2016 9 / 17
identified by MINDy were included (6 modulators). Thirdly, all of the in-modulators (S2 Fig) that positively regulated SPDEF (3 modulators) were included in the analysis. Finally, the long list of positive FOXA1 modulators was ranked by \( P \)-value and a cut-off of 0.001 was employed, with consensus between the two cohorts. This gave a total of 189 positive post-transcriptional modulators of SPDEF and FOXA1 to be tested (S2 Table; 6 positive modulators of SPDEF, including one that is also a positive modulator of FOXA1 and GATA3, 180 positive modulators of FOXA1, including some that are also positive modulators of ESR1 and/or GATA3, and 3 in-modulators that positively regulate SPDEF).

**MINDy-identified modulators of breast cancer risk TF activity affect ER\(^+\) breast cancer cell proliferation**

To test the activity of these 189 modulators, ZR751 (highest expression of SPDEF and FOXA1; Fig 3) and HB2 cells were transfected with siRNAs targeting these modulators and cell proliferation was assayed. Statistical analysis of proliferation data was performed using the `compareGrowthCurves` command in the `statmod` package in R (http://CRAN.R-project.org/package=statmod), with multiple testing correction carried out using the Benjamini-Hochberg method. Using this statistical approach, we found that 55 modulators significantly inhibited growth of the ZR751 cell line without affecting proliferation of the HB2 cell line (Fig 5, S3 Table, S3 Fig). In this regard, these 55 modulators behave like the TFs they are positively modulating, in that their reduced expression/activity results in a perturbed proliferative response, which is cell type-specific. Our positive controls, SPDEF and FOXA1, are towards the far right of the plot displayed in Fig 5, confirming that knocking down expression of the TFs has a large effect on ZR751 cell proliferation compared with HB2 cell proliferation. Knocking down expression of 14 of the 189 modulators inhibited growth of both cell lines, presumably as a result of off-target effects not associated with SPDEF/FOXA1 modulation. For example, siRNA directed against \( CCND1 \) (encodes cyclin D1, an important cell cycle protein), was used as a control in the assay as knocking down its expression should reduce proliferation in all cell lines, not just those dependent on SPDEF and FOXA1 activity. Any modulator which showed a response pattern similar to \( CCND1 \) in the assay was disregarded. Overall, we found that 53 of the FOXA1 modulators had an effect on proliferation and two SPDEF modulators, MLS3 and ARHGEF2, significantly reduced proliferation specifically in ZR751 cells.

**Validated modulators are frequently mutated in breast cancer**

To obtain orthogonal data for the importance of the identified modulators we examined whether the genes of the 55 validated modulators are altered in cancer. Studies with available copy number alteration (CNA) data show that amplification of the modulator genes is very...
common in breast cancer [15–17] (Fig 6A). Moreover, mutations in these genes are present in up to 10% of the samples tested in the available studies [15–20]. Collectively, our 55 modulators have a significantly increased frequency of alterations in comparison to both random genes and annotated cancer-related genes for which mutations have been causally implicated in cancer [21] (Fig 6B). These data support the functional importance of the identified modulators.

MINDy-identified modulators of SPDEF activity affect SPDEF-driven transcription

As outlined in the introduction, modulators identified by MINDy may post-transcriptionally and/or post-translationally modify the TF, affect its cellular localisation or turnover, form a transcriptional complex with the TF, or compete for its DNA binding site. Ultimately, the modulator must alter the ability of the TF to drive transcription. We tested this on the two SPDEF modulators that affected ZR751 cell proliferation (Fig 5). Transcriptional activity was assayed by generating SPDEF-driven luciferase reporter constructs (Fig 7A) to ask if removal of the MINDy-identified modulators of SPDEF would alter the luciferase read-out. As a positive control in our assay we transfected the SPDEF-luciferase reporter construct into ZR751 cells and observed that luciferase luminescence was reduced by 46% when siRNA directed against SPDEF was co-transfected (Fig 7B). Similarly, when siRNA directed against MSL3 and ARHGEF2, two validated modulators of SPDEF, was transfected into ZR751 cells, luciferase luminescence was reduced by 30% and 26%, respectively (Fig 7C), without having any affect on SPDEF expression levels (Fig 7D). These two SPDEF modulators were identified by
MINDy, and the proliferation screen (Fig 5) suggests that they are required by ZR751 cells for growth. These data therefore show that MINDy is able to identify biologically-relevant modulators of TFs that can alter the TF’s transactivational activity.

Discussion

Here we demonstrate that the MINDy algorithm is able to identify post-transcriptional modulators of key TFs of ER+ breast cancer. We have found and validated novel modulators of
FOXA1 and SPDEF, both of which are of special interest in breast cancer. FOXA1 may be a particularly relevant therapeutic target since cancers that have become resistant to hormone treatment may still be dependent on FOXA1 for proliferation [22]. Also, SPDEF may be an important regulator of cell metastasis, not just in prostate but also in breast cell lines [23]. Both TFs also affect the risk of developing breast cancer [4] and are therefore of interest in designing preventative strategies.

To seek experimental validation of the candidate modulators, we transfected siRNA libraries directed against positive modulators into SPDEF and FOXA1-dependent and -independent cell lines, and potential biologically-relevant modulators were identified on the basis of affecting proliferation in one, but not the other cell line. Of the 189 modulators selected for study, over a quarter (55) were shown to affect ER$^+$ breast cancer cell growth when compared to a cell line that does not require the TFs in order to proliferate. The primary function of 25 out of these 55 modulators is classed as having a role in either cell cycle or transcription (GO term analysis), supporting the idea that these modulators might affect the activity of a TF required for cell proliferation. Validation assays based on other cellular phenotypes or specific protein function may be able to validate additional modulators identified in our computational analysis.

As yet, we do not understand why MINDy was able to identify such a large number of modulators of FOXA1, while only finding relatively few factors that affected ESR1, given that these two TFs share many binding sites and target genes [22,24,25]. One possible explanation may lie in the fact that ESR1 activity depends on the presence of estrogen, which may not be universally available within the tumour. The link between gene expression and target genes may therefore be less strong and MINDy less able to find modulators. There may be other confounding factors. Regulatory processes associated with the cell cycle are largely modulated by protein phosphorylation cascades. Such alterations, potentially leading to protein degradation, may break the correlation of gene expression between the TF and its targets that the MINDy algorithm relies on.

In conclusion, our analysis of the effect of potential modulators of SPDEF and FOXA1 activity in ER$^+$ breast cancer suggests that MINDy and other such computational tools have the power to identify valid modulators of TF activity that warrants further follow-up work. For SPDEF we found two modulators which have the ability to reduce SPDEF-driven transcription. MLS3 is a component of the MLS complex responsible for the majority of histone H4 acetylation at Lys16. GO annotations for this nuclear protein include chromatin organisation and transcription. ARHGEF2 is a primarily cytoplasmic Rho/Rac guanine nucleotide exchange factor involved in signalling by G-protein coupled receptors. Further functional follow-up analysis of these proteins in the context of ER$^+$ breast cancer may be warranted. Also, a large

Fig 7. MINDy-identified modulators of SPDEF activity affect SPDEF-driven transcription. (A) Schematic depiction of the reporter construct used in the luciferase reporter assays. (B) Luciferase luminescence in MCF-7 cells 24 hours post-transfection of reporter construct containing SPDEF binding domains (SPDEF), normalised to β-galactosidase expression ($n = 9$, three separate experiments, $P<0.001$ (***), one-way ANOVA and SNK correction, error bars = SEM). pGL3 Basic/pGL3 Control: control luciferase reporter vectors; Empty Lux2CP: Empty vector control; siSPDEF: SPDEF siRNA treatment. (C) Luciferase luminescence 24 hours post-transfection of reporter construct containing SPDEF binding domains into MCF-7 cells treated with siRNA directed against SPDEF, MSL3 and ARHGEF2, normalised to β-galactosidase expression ($n = 9$, three separate experiments, $P<0.001$ (***), one-way ANOVA and SNK correction, error bars = SEM). CTL: untransfected control; siScrambled: non-targeting siRNA control. (D) Relative mRNA expression of SPDEF in MCF-7 cells following transfection with siRNA directed against SPDEF, MSL3 and ARHGEF2. All data were normalised to DGUOK expression ($n = 10$, two separate experiments, $P<0.001$ (***), one-way ANOVA and SNK correction, error bars = SEM). CTL: untransfected control; siScrambled: non-targeting siRNA control.

doi:10.1371/journal.pone.0168770.g007
number of FOXA1 modulators that can affect proliferation were found and future studies will have to assess their contribution to driving the cancer phenotype.

TFs are notoriously difficult targets to drug [26]. Therefore, the availability of tools that can accurately identify modulators of TFs, which could prove to be more tractable therapeutic targets, is very appealing.

Supporting Information

S1 Fig. Negative modulators of ESR1, GATA3, FOXA1 and SPDEF, identified by MINDy. (PDF)

S2 Fig. “In-modulators” of ESR1, GATA3, FOXA1 and SPDEF, identified by MINDy. The in-modulators refer to those modulators that lie in-between two or more of the TFs of interest, i.e. their activity is modulated by one of the TFs and they modulate the activity of another of the TFs. (PDF)

S3 Fig. Example growth curves. 12 of the 69 significant (P-value = 0.005) modulator gene example growth curves obtained in ZR751 breast cancer cells using the growth curve analysis are shown. Red: test gene siRNA; Green: non-targeting control siRNA. Statistical analysis of proliferation data was performed using the compareGrowthCurves command in the statmod package in R (http://CRAN.R-project.org/package=statmod). Multiple testing correction was achieved using the Benjamini-Hochberg method. (PDF)

S1 Table. siRNA plate layout. (XLS)

S2 Table. Modulator list. (XLSX)

S3 Table. MINDy-identified modulator genes showing statistically significant impact on proliferation of ZR751 cells compared to control. (DOCX)

Acknowledgments

We thank the Biorepository, Bioinformatics and Research Instrumentation Core Facilities at The CRUK Cambridge Institute for their help and expertise.

Author Contributions

Conceptualization: TMC MAAC BAJP KBM.

Formal analysis: TMC MAAC.

Funding acquisition: KBM BAJP.

Investigation: TMC MAAC.

Methodology: TMC MAAC BAJP KBM.

Software: MAAC.

Supervision: BAJP KBM.
Validation: TMC.

Visualization: TMC MAAC KBM.

Writing – original draft: TMC MAAC BAJP KBM.

Writing – review & editing: TMC MAAC BAJP KBM.

References

1. Bansal M, Califano A (2012) Genome-wide dissection of posttranscriptional and posttranslational interactions. Methods Mol Biol 786: 131–149. doi: 10.1007/978-1-61779-292-2_8 PMID: 21938624

2. Wang K, Saito M, Bisikirska BC, Alvarez MJ, Lim WK, Rajbahadari P, et al. (2009) Genome-wide identification of post-translational modulators of transcription factor activity in human B cells. Nat Biotechnol 27: 829–839. doi: 10.1038/nbt.1563 PMID: 19741643

3. Campbell TM, Castro MA, de Santiago I, Fletcher MN, Halim S, Prathalingam R, et al. (2016) FGFR2 risk SNPs confer breast cancer risk by augmenting oestrogen responsiveness. Carcinogenesis 37: 741–750. doi: 10.1093/carcin/bgw065 PMID: 27236187

4. Fletcher MN, Castro MA, Wang X, de Santiago I, O’Reilly M, Chin SF, et al. (2013) Master regulators of FGFR2 signalling and breast cancer risk. Nat Commun 4: 2464. doi: 10.1038/ncomms3464 PMID: 24043118

5. Jozwik KM, Carroll JS (2012) Pioneer factors in hormone-dependent cancers. Nat Rev Cancer 12: 381–385. doi: 10.1038/nrc3263 PMID: 22555282

6. Takaku M, Grimm SA, Wade PA (2015) GATA3 in Breast Cancer: Tumor Suppressor or Oncogene? Gene Expr 16: 163–168. doi: 10.3727/105221615X14399878166113 PMID: 26637396

7. Steffen JJ, Koul HK (2011) Prostate derived ETS factor (PDEF): a putative tumor metastasis suppressor. Cancer Lett 310: 109–117. doi: 10.1016/j.canlet.2011.06.011 PMID: 21764212

8. Sood AK, Kim H, Gerads J (2012) PDEF in prostate cancer. Prostate 72: 592–596. doi: 10.1002/pros.21461 PMID: 21796651

9. Sood AK, Saxena R, Groth J, Desouki MM, Cheewakriangkrai C, Rodabaugh KJ, et al. (2007) Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression. Hum Pathol 38: 1628–1638. doi: 10.1016/j.humpath.2007.03.010 PMID: 17521701

10. Turcotte S, Forget MA, Beauseigle D, Nassif E, Lapointe R (2007) Prostate-derived Ets transcription factor overexpression is associated with nodal metastasis and hormone receptor positivity in invasive breast cancer. Neoplasia 9: 788–796. PMID: 17971898

11. Feldman RJ, Sementchenko VI, Gayed M, Fraig MM, Watson DK (2003) PDEF expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res 63: 4626–4631. PMID: 12907642

12. Oettgen P, Finger E, Sun Z, Akbarali Y, Thamrongsaik U, Boltax J, et al. (2000) PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biol Chem 275: 1216–1225. PMID: 10825666

13. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–408. doi: 10.1006/meth.2001.1262 PMID: 11846609

14. Castro MA, de Santiago I, Campbell TM, Vaughn C, Hickey TE, Ross E, et al. (2016) Regulators of genetic risk of breast cancer identified by integrative network analysis. Nature Genetics 48: 12–21. doi: 10.1038/ng.3458 PMID: 26618344

15. (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61–70. doi: 10.1038/nature11412 PMID: 23000897

16. Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, et al. (2015) Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell 163: 506–519. doi: 10.1016/j.cell.2015.09.033 PMID: 26451490

17. Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H, et al. (2015) Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518: 422–426. doi: 10.1038/nature13952 PMID: 25470049

18. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, et al. (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486: 405–409. doi: 10.1038/nature11154 PMID: 22722202
19. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486: 395–399. doi: 10.1038/nature10933 PMID: 22495314

20. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486: 400–404. doi: 10.1038/nature11017 PMID: 22722201

21. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. (2015) COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res 43: D805–811. doi: 10.1093/nar/gku1075 PMID: 25355519

22. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS (2011) FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 43: 27–33. doi: 10.1038/ng.730 PMID: 21151129

23. Steffan JJ, Koul S, Meacham RB, Koul HK (2012) The transcription factor SPDEF suppresses prostate tumor metastasis. J Biol Chem 287: 29968–29978. doi: 10.1074/jbc.M112.379396 PMID: 22761428

24. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, et al. (2006) Genome-wide analysis of estrogen receptor binding sites. Nat Genet 38: 1289–1297. doi: 10.1038/ng1901 PMID: 17013392

25. Welboren WJ, Stunnenberg HG, Sweep FC, Span PN (2007) Identifying estrogen receptor target genes. Mol Oncol 1: 138–143. doi: 10.1016/j.molonc.2007.04.001 PMID: 19383291

26. Verdine GL, Walensky LD (2007) The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin Cancer Res 13: 7264–7270. doi: 10.1158/1078-0432.CCR-07-2184 PMID: 18094406